anti-Human LY96 Antikörper für Flow Cytometry

Recommended LY96 Antibody (geliefert von: Anmelden zum Anzeigen )

Antigen
Lymphocyte Antigen 96 (LY96) Antikörper
  • MD2
  • ESOP-1
  • MD-2
  • ly-96
  • Ly-96
  • Md2
  • lymphocyte antigen 96
  • LY96
  • Ly96
Reaktivität
Human
112
42
27
2
1
1
1
1
Wirt
Maus
84
35
Klonalität
Monoklonal
Konjugat
Dieser LY96 Antikörper ist konjugiert mit Biotin
11
10
3
2
2
2
Applikation
Flow Cytometry (FACS)
105
50
48
15
12
5
5
5
5
4
3
2
2
1
1
Optionen
Hersteller
Anmelden zum Anzeigen
Hersteller Produkt- Nr.
Anmelden zum Anzeigen
Request

Produkt kostenlos erhalten?

Für Ihre Validierungsdaten erstatten wir Ihnen den vollen Kaufpreis. Ich möchte dieses Produkt validieren

Mehr erfahren

Produktnummer ABIN2192086
$ 407.22
Zzgl. Versandkosten $45.00
Relevance Score ABIN Application Konjugat Host Isotype Epitope Hersteller Clonality References Details
17.311333 ABIN2192087 FACS FITC Mouse Anmelden zum Anzeigen 18H10 4
17.311333 ABIN2192085 FACS InhA Mouse Anmelden zum Anzeigen 18H10 4
1 ABIN1830497 FACS Biotin Mouse IgG1 Anmelden zum Anzeigen 13A77 0
1 ABIN2312428 FACS FITC Mouse IgG2b Anmelden zum Anzeigen 13A58 0
1 ABIN2312425 FACS Mouse IgG2b Anmelden zum Anzeigen 13A58 0

General

Antigen Lymphocyte Antigen 96 (LY96) Antikörper
Reaktivität Human
(112), (42), (27), (2), (1), (1), (1), (1)
Wirt Maus
(84), (35)
Klonalität (Klon)
Monoklonal   ( )
Konjugat Dieser LY96 Antikörper ist konjugiert mit Biotin
(11), (10), (3), (2), (2), (2)
Applikation Flow Cytometry (FACS)
(105), (50), (48), (15), (12), (5), (5), (5), (5), (4), (3), (2), (2), (1), (1)
Pubmed 4 Publikationen vorhanden
Hersteller Anmelden zum Anzeigen

Produktdetails anti-LY96 Antikörper

Target Details LY96 Anwendungsinformationen Handhabung Referenzen für anti-LY96 Antikörper (ABIN2192086) Bilder
Sterilität 0.2 μm filtered
Immunogen TLR4/MD-2 expressing CHO cells/ chimeric TLR4/MD-2 fusion protein
Klon 18H10
Plasmids, Primers & others

Target Details LY96

Produktdetails anti-LY96 Antikörper Anwendungsinformationen Handhabung Referenzen für anti-LY96 Antikörper (ABIN2192086) Bilder zurück nach oben
Antigen
Andere Bezeichnung Md-2 (LY96 Antibody Abstract)
Hintergrund The monoclonal antibody 18H10 reacts with MD-2, an accessory molecule of the Toll-like receptor 4 (TLR4, CD284). TLRs belong to a family of proteins that specifically recognizes and senses microbial products. They are highly conserved throughout evolution and act as innate immune recognition receptors against many pathogens. TLR4 is a functional receptor for gram-negative bacterial lipopolysaccharides (LPS). TLR4 associates with MD-2 which is absolutely required for LPS-induced activation of TLR4. MD-2 exists as a cell surface protein in association with TLR4. It also exists as secreted forms consisting of MD-2 monomers and multimers (sMD-2). Circulating sMD-2 is mainly present as a doublet of ~20 and 25 kD, representing differentially glycosylated forms. Unlike TLR4, sMD-2 binds directly LPS without the need of soluble CD14 (sCD14). However, LPS-MD-2 interactions are increased when LPS is pretreated with CD14. Only monomeric sMD-2 is biologically active and able to associate with TLR4 and LPS. sMD-2 circulates in plasma of healthy individuals as a non-active, polymeric protein. In septic plasma, the total amount of sMD-2 was strongly elevated and contained both sMD-2 polymers and monomers. Soluble MD-2 is proposed to be an important mediator of organ inflammation during sepsis. During experimental human endotoxemia, the monomeric and total sMD-2 content in plasma increased with the kinetics of an acute phase protein. This parallels enhanced TLR4 costimulatory activity. In vitro studies revealed that sMD-2 release appears to be restricted to endothelial and dendritic cells. The monoclonal antibody 18H10 reacts with MD-2. However, it does not react with sMD-2. In addition, the monoclonal antibody 18H10 is able to inhibit bacterial binding to MD-2. Aliases Lymphocyte antigen 96, ESOP-1, LY96
Pathways TLR Signalweg, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Toll-Like Receptors Cascades

Anwendungsinformationen

Produktdetails anti-LY96 Antikörper Target Details LY96 Handhabung Referenzen für anti-LY96 Antikörper (ABIN2192086) Bilder zurück nach oben
Applikations-hinweise For flow cytometry dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
Beschränkungen Nur für Forschungszwecke einsetzbar

Handhabung

Produktdetails anti-LY96 Antikörper Target Details LY96 Anwendungsinformationen Referenzen für anti-LY96 Antikörper (ABIN2192086) Bilder zurück nach oben
Buffer PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.
Konservierungs-mittel Sodium azide
Vorsichtsmaßnahmen This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung 4 °C
Informationen zur Lagerung Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Haltbarkeit 12 months

Referenzen für anti-LY96 Antikörper (ABIN2192086)

Produktdetails anti-LY96 Antikörper Target Details LY96 Anwendungsinformationen Handhabung Bilder zurück nach oben
Produkt verwendet in:

Tissières, Dunn-Siegrist, Schäppi, Elson, Comte, Nobre, Pugin: "Soluble MD-2 is an acute-phase protein and an opsonin for Gram-negative bacteria." in: Blood, Vol. 111, Issue 4, pp. 2122-31, 2008

Daubeuf, Mathison, Spiller, Hugues, Herren, Ferlin, Kosco-Vilbois, Wagner, Kirschning, Ulevitch, Elson: "TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 179, Issue 9, pp. 6107-14, 2007

Elson, Dunn-Siegrist, Daubeuf, Pugin: "Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria." in: Blood, Vol. 109, Issue 4, pp. 1574-83, 2007

Pugin, Stern-Voeffray, Daubeuf, Matthay, Elson, Dunn-Siegrist: "Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock." in: Blood, Vol. 104, Issue 13, pp. 4071-9, 2004